Vipidia™, fixed-dose combinations Vipdomet™ and Incresync™ label updates

Takeda Pharmaceuticals International GmbH ('Takeda') has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued positive opinions for updates to the Summary of Product Characteristics (SmPC) for Vipidia™ (alogliptin) and the fixed-dose combination (FDC) therapies Vipdomet™ (alogliptin and metformin) and Incresync™ (alogliptin and pioglitazone).
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Diabetes Latest News Source Type: news